Uncategorized
Actavis completes $70.5 billion acquisition of Allergan
Actavis announced today that it has completed its acquisition of Allergan in a transaction valued at approximately $70.5 billion in cash and equity.In a separate press release, the company also announced two former members of the Allergan board of directors, Michael R. Gallagher, lead independent director, and Peter J. McDonnell, MD, have been named to the Actavis board of directors. David E.I. Pyott, chairman and CEO of Allergan, elected not to join the board of directors but will continue to serve as chairman of The Allergan Foundation, a U.S.-based private (Read more...)